Trovagene, inc. (TROV)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net Income (Loss) Attributable to Parent

-16,414

-16,461

-24,906

-39,203

-27,471

-14,325

-11,810

-11,565

Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of assets

0

-362

-455

-577

-4

24

-

-

Impairment loss

0

187

589

0

-

-

-

-

Net gain on disposal of fixed assets

-

-

-

-

-

-

-22

4

Depreciation and amortization

494

859

1,247

1,069

378

234

130

41

Stock-based compensation expense

884

2,174

4,012

7,504

3,946

2,070

1,979

532

Gain (Loss) on Extinguishment of Debt

0

17

-1,655

0

-

-

-

-

Accretion of final fee premium

-

-

293

390

-

-

-

-

Amortization of discount on debt

-

-

113

173

346

248

-

-

Net realized loss on short-term investments

-

-

-6

0

-

-

-

-

Amortization of discount on debt

-

-

-

-

88

57

-

-

Amortization of premiums on short-term investments

-

-

-9

-107

0

0

-

-

Deferred rent

0

-59

140

201

-

-

-

-

Deferred rent

-

-

-

-

0

0

-

-

Interest income accrued on short-term investments

-

-

90

84

0

0

-

-

Unrealized Gain (Loss) on Derivatives

28

617

3,401

2,462

-726

1,425

-1,084

-6,720

Release of clinical trial funding commitment

703

0

-

-

-

-

-

-

Stock and warrant issued in connection with consulting services

-

-

-

-

-

-

198

164

Changes in operating assets and liabilities:
Other assets

54

23

0

789

37

0

-25

-

Accounts receivable and unbilled receivable

35

-19

-23

1

42

-22

-89

69

Prepaid expenses

-115

-21

208

277

420

216

92

17

Operating lease right-of-use assets

-302

0

-

-

-

-

-

-

Accounts payable and accrued expenses

1,455

214

-2,940

2,157

361

632

1,055

-737

Operating lease liabilities

-776

0

-

-

-

-

-

-

Other liabilities

86

22

-

-

-

-

-

-

Net cash used in operating activities

-13,267

-13,199

-

-

-

-

-

-

Net cash used in operating activities

-

-

-23,281

-31,039

-22,119

-12,727

-7,317

-4,934

Investing activities:
Capital expenditures

67

5

101

823

2,241

363

649

274

Proceeds from disposals of capital equipment

0

27

1

0

7

63

0

4

Maturities of short-term investments

-

-

16,431

13,750

0

0

-

-

Purchases of short-term investments

0

31

8,804

37,760

0

0

-

-

Sales of short-term investments

0

31

16,434

0

-

-

-

-

Net cash used in investing activities

-67

22

-

-

-

-

-

-

Net cash used in investing activities

-

-

23,962

-24,833

-2,233

-299

-649

-270

Financing activities:
Proceeds from sales of common stock and warrants

8,817

11,779

11,727

2,364

61,215

0

18,829

15,323

Proceeds from sales of Series B Convertible Preferred Stock, net of expenses of $0 and $497,617 respectively

0

4,386

0

-

-

-

-

-

Costs related to the clinical trial funding commitment

-40

0

-

-

-

-

-

-

Payments of Stock Issuance Costs

-

-

866

79

-

-

-

-

Proceeds from exercise of warrants

3,299

1,612

0

-

1,389

-

3,599

-

Proceeds from exercise of options

-

-

-

366

860

0

38

0

Borrowings under equipment line of credit

-

-

-

792

1,086

-

515

-

Repayments under equipment line of credit

0

1,200

626

52

0

515

0

-

Proceeds from borrowings under long-term debt, net of costs

-

-

-

7,805

-

15,000

0

-

Payment upon debt extinguishment

0

175

1,613

0

-

-

-

-

Net cash provided by financing activities

12,077

16,403

-

-

-

-

-

-

Net change in cash and cash equivalents

-1,257

3,227

-

-

-

-

-

-

Repayments of long-term debt

-

-

15,000

8,896

0

0

-

-

Net cash provided by financing activities

-

-

-6,378

2,301

64,551

14,484

22,983

15,324

Effect of exchange rate changes on cash and cash equivalents

-

-

7

-5

0

0

-

-

Net change in cash and cash equivalents

-

-

-5,689

-53,577

40,199

1,456

15,017

10,119

Supplementary disclosure of cash flow activity:
Cash paid for taxes

0

0

0

4

16

2

7

-

Cash paid for interest

0

22

-

-

-

-

-

-

Cash paid for interest

-

-

668

1,103

1,061

425

9

-

Supplemental disclosure of non-cash investing and financing activities:
Reclassification of derivative financial instruments to additional paid-in capital

-

-

-

-

-435

0

5,417

-

Correction of error in derivative financial instruments

-

-

-

-

-

-

-

274

Preferred stock dividend payable on Series A Convertible Preferred Stock

24

24

24

24

24

23

29

38

Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock

-

-

0

-

-

-

-

-

Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment

1,675

0

-

-

-

-

-

-

Amortization of debt costs and final payment

-

-

113

173

-

-

-

-

Reclassification of derivative financial instruments to additional paid in capital

-

-

-

-

-

-

-

3,317

Leasehold improvements paid for by lessor

-

-

-

1,860

0

0

-

-

Common stock issued upon conversion of Convertible Preferred Stock

-

-

0

-

-

-

-

-

Series B Convertible Preferred Stock
Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock

0

2,769

-

-

-

-

-

-

Common stock issued upon conversion of Convertible Preferred Stock

0

0

-

-

-

-

-

-

Series C Convertible Preferred Stock
Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock

268

0

-

-

-

-

-

-

Common stock issued upon conversion of Convertible Preferred Stock

0

0

-

-

-

-

-

-